Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Nature Medicine

Volumn 11, Issue 11, 2005, Pages 1170-1172

  Fätkenheuer, Gerd ^a   Pozniak, Anton L ^b   Johnson, Margaret A ^c   Plettenberg, Andreas ^d   Staszewski, Schlomo ^e   Hoepelman, Andy I M ^f   Saag, Michael S ^g   Goebel, Frank D ^h   Rockstroh, Jürgen K ⁱ   Dezube, Bruce J ^j   Jenkins, Tim M ^k   Medhurst, Christine ^k   Sullivan, John F ^k   Ridgway, Caroline ^k   Abel, Samantha ^k   James, Ian T ^k   Youle, Mike ^c   Van Der Ryst, Elna ^k  

^a UNIVERSITY OF COLOGNE   (Germany)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF BONN   (Germany)

^j HARVARD MEDICAL SCHOOL   (United States)

^k PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE II; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CCR5; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 30744447460     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1319     Document Type: Article

References (14)

1. Struble, K. et al. AIDS 19, 747-756 (2005).
2. Dean, M. et al. Science 273, 1856-1862 (1996).
3. Eugen-Olsen, J. et al. AIDS 11, 305-310 (1997).
4. Meyer, L. et al. AIDS 11, F73-F78 (1997).
5. Kuhmann, S.E. et al. J. Virol. 78, 2790-2807 (2004).
6. Maeda, K. et al. J. Virol. 78, 8654-8662 (2004).
7. Strizki, J.M. et al. Proc. Natl. Acad. Sci. USA 198, 12718-12723 (2001).
8. Takashima, K. et al. Antimicrob. Agents Chemother. 45, 3538-3543 (2001).
9. Dorr, P. et al. Antimicrob. Agents Chemother. (in the press).
10. Maggiolo, F. et al. HIV Clin. Trials 3, 371-378 (2002).
11. Adkins, J.C. & Noble, S. Drugs 56, 1055-1064 (1998).
12. Gulick, R.M. et al. N. Engl. J. Med. 337, 734-739 (1997).
13. McCallister, S. et al. J. Acquir. Immune Defic. Syndr. 35, 376-382 (2004).
14. Lalezari, J. et al. AIDS 19, 1443-1448 (2005).